440 related articles for article (PubMed ID: 35578182)
1. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.
Driessen MT; Cohen JM; Patterson-Lomba O; Thompson SF; Seminerio M; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 Apr; 23(1):47. PubMed ID: 35410121
[TBL] [Abstract][Full Text] [Related]
3. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
[TBL] [Abstract][Full Text] [Related]
6. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
7. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
9. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
10. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine.
Ashina M; Amin FM; Kokturk P; Cohen JM; Konings M; Tassorelli C; Lyras L; Mitsikostas DD
Pain Manag; 2021 Nov; 11(6):647-654. PubMed ID: 34105377
[TBL] [Abstract][Full Text] [Related]
11. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
12. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
13. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
Silberstein SD; Cohen JM; Seminerio MJ; Yang R; Ashina S; Katsarava Z
J Headache Pain; 2020 Sep; 21(1):114. PubMed ID: 32958075
[TBL] [Abstract][Full Text] [Related]
14. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
15. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
Sevivas H; Fresco P
Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan.
Suzuki S; Suzuki K; Shiina T; Haruyama Y; Hirata K
Front Neurol; 2023; 14():1220285. PubMed ID: 37483436
[TBL] [Abstract][Full Text] [Related]
18. Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M; Mitsikostas DD; Ramirez Campos V; Barash S; Ning X; Diener HC
Headache; 2023; 63(10):1351-1358. PubMed ID: 37955395
[TBL] [Abstract][Full Text] [Related]
19. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
[TBL] [Abstract][Full Text] [Related]
20. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
McAllister P; Lamerato L; Krasenbaum LJ; Cohen JM; Tangirala K; Thompson S; Driessen M; Casciano J; Dotiwala Z; Mauskop A
J Headache Pain; 2021 Dec; 22(1):156. PubMed ID: 34930112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
